Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of JAK2 enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with JAK2 signaling with the compounds and compositions of the disclosure.

Abstract: An assistive device detects deterioration of a person's health, e.g., in an at-home setting, and offers guidance/prompting designed to address or avoid a deteriorated state, based on the person's personalized care plan. A deteriorated state is detected by analysis of multi-faceted data relating to any characteristics usable to assess the person's health, e.g., biometric, activity, or environmental data, as well as data from interactive health assessment screenings delivered via the assistive device. The care plan can contain actions identified by a clinician, e.g., as part of a post-discharge safety plan, or self-identified actions, which may be stabilizing coping mechanism activities. The device may also provide reminders of clinician visits, wellbeing/other activities, medications, and daily affirmations. The device may be configured as a mirror to display the person's image and an avatar with which the person may communicate in a dialog session to provide for a welcoming and engaging experience.

Abstract: The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

Abstract: The invention relates to crystalline forms of an ALK2 inhibitor, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to pharmaceutical uses of the crystalline forms.

Abstract: A catheterization training device includes a rigid housing defining an internal cavity, and a leg/torso body model constructed of lightweight material and storable within the internal cavity. The body model houses a urinary bladder model housed and a proximal urethra model defining a first canal in fluid communication with said urinary bladder model and terminating in a connector. The device further includes at least one genitalia accessory having a configuration of one of human male and human female genitalia. Each genitalia accessory defines a distal urethral model comprising a second canal terminating in a corresponding connector operable to form a mechanical interconnection with the connector of the body model to form a fluid-tight interconnection therewith, and a continuous canal through the distal urethra model and the proximal urethra model and into the urinary bladder model.

Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of CDK enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with CDK signaling with the compounds and compositions of the disclosure.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

Abstract: The invention relates to crystalline forms of an ALK2 inhibitor, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to pharmaceutical uses of the crystalline forms.

Abstract: Trisubstituted bicyclic heterocyclic compounds (e.g., pyridopyrimidinones) and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

Abstract: Provided are isotopologues of isoquinolinone and quinazolinone compounds of formula (AB?) that modulate PI3 kinase activity, processes for the preparation of the compounds, pharmaceutical compositions comprising the compounds, and methods of treatment of diseases and disorders using the compounds or pharmaceutical compositions.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.